Related Experiment Videos
That's how you make drugs!
1CEO & Patient Advocate, Inspire2Live, Amsterdam, The Netherland. peter.kapitein@gmail.com.
Abstract:
Although the science is able to proof that a drug works for the BRCA mutation in breast cancer, prostate cancer and pancreatic cancer (and maybe in other BRCA-mutated cancers) we stick to the registration path of doing phase 1, 2 and 3 trials based on organs. With the knowledge of today and the practice of personalized medicine we are able to give the drug olaparib much faster and save lives or at least extend lives with a good quality of life. This can be done differently if patients are involved in the process of determining the research, designing the trials and organizing the trials. If done properly we help patients in the first place and all the stakeholders will benefit as well.
Insights
Olaparib is effective for BRCA-mutated cancers, but traditional trials delay access. Patient involvement can accelerate personalized medicine, benefiting patients and stakeholders.
Area of Science:
- Oncology
- Genetics
- Clinical Trial Design
Background:
- Olaparib demonstrates efficacy in BRCA-mutated cancers, including breast, prostate, and pancreatic.
- Current drug approval pathways rely on organ-specific trials, potentially delaying patient access.
Purpose of the Study:
- To advocate for a faster drug approval process for olaparib in BRCA-mutated cancers.
- To highlight the potential of personalized medicine and patient involvement in clinical research.
Main Methods:
- Review of existing scientific evidence on olaparib's efficacy.
- Analysis of current clinical trial registration pathways.
- Exploration of patient-centric approaches in research and trial design.
Main Results:
- Olaparib is scientifically validated for specific BRCA mutations.
- Organ-based trial structures impede rapid deployment of effective treatments.
- Patient engagement can streamline research and development.
Conclusions:
- Accelerating olaparib's accessibility through personalized medicine strategies is feasible.
- Integrating patients into research processes can improve outcomes and stakeholder benefits.
- Rethinking trial design can enhance the delivery of targeted cancer therapies.